These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27919352)

  • 21. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Li JJ
    Lipids Health Dis; 2014 Dec; 13():188. PubMed ID: 25496400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
    Sponder M; Campean IA; Dalos D; Emich M; Fritzer-Szekeres M; Litschauer B; Bergler-Klein J; Graf S; Strametz-Juranek J
    Pol Arch Intern Med; 2017 Aug; 127(7-8):506-511. PubMed ID: 28607329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
    Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
    BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
    Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
    J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
    Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S; Rodríguez-Pérez C; Ramprasath VR; Segura-Carretero A; Jones PJ
    Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.
    Gao J; Yang YN; Cui Z; Feng SY; Ma J; Li CP; Liu Y
    Lipids Health Dis; 2021 May; 20(1):56. PubMed ID: 34044829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Bojanin D; Vekic J; Milenkovic T; Vukovic R; Zeljkovic A; Stefanovic A; Janac J; Ivanisevic J; Mitrovic K; Miljkovic M; Spasojevic-Kalimanovska V
    Atherosclerosis; 2019 Jan; 280():14-20. PubMed ID: 30453116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study.
    Holme I; Høstmark AT; Anderssen SA
    J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
    Li S; Zhao X; Zhang Y; Zhu CG; Guo YL; Wu NQ; Xu RX; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
    Oncotarget; 2017 Feb; 8(7):12333-12341. PubMed ID: 27713142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease.
    Rasouli M; Kiasari AM; Mokhberi V
    Clin Chem Lab Med; 2006; 44(8):1015-21. PubMed ID: 16879071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
    Du Q; Yu XJ; Li HJ; Guan SQ; Zhang ZY; Mei YF
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):655-659. PubMed ID: 28870033
    [No Abstract]   [Full Text] [Related]  

  • 37. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study.
    Erbel R; Lehmann N; Churzidse S; Möhlenkamp S; Moebus S; Mahabadi AA; Schmermund A; Stang A; Dragano N; Grönemeyer D; Seibel R; Kälsch H; Bauer M; Bröcker-Preuss M; Mann K; Jöckel KH;
    Atherosclerosis; 2013 Aug; 229(2):531-40. PubMed ID: 23701995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
    Cariou B; Guérin P; Le May C; Letocart V; Arnaud L; Guyomarch B; Pichelin M; Probst V
    Diabetes Metab; 2017 Dec; 43(6):529-535. PubMed ID: 28865748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.
    Sokolov V; Helmlinger G; Nilsson C; Zhudenkov K; Skrtic S; Hamrén B; Peskov K; Hurt-Camejo E; Jansson-Löfmark R
    J Lipid Res; 2019 Sep; 60(9):1610-1621. PubMed ID: 31292220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.